You are here: Industry Insights > Market News > Centre provides over 42 crore vaccine doses to states and UTs

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

Centre provides over 42 crore vaccine doses to states and UTs

expresspharmaJuly 20, 2021

Tag: vaccination , COVID-19 vaccine , Supply

Favorites

In the new phase of the universalisation of the COVID-19 vaccination drive, the Centre will procure and supply (free of cost) 75 per cent of the vaccines being produced by the vaccine manufacturers in the country to states and Union Territories (UTs).

So far, over 42.15 crore (42,15,43,730) vaccine doses have been provided to states and UTs through all sources, and a further 71,40,000 doses are in the pipeline.

Of this, the total consumption, including wastages, is 40,03,50,489 doses (as per the data available at 8 AM today).

Over 2.11 crore (2,11,93,241) balance and unutilised COVID vaccine doses are still available with the states and UTs, and private hospitals to be administered.

Previous:Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Next:Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Centre provides over 42 crore vaccine doses to states and UTs | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Factory Supply Sea Moss+Shilajit Capsule

Factory supply CAS:630-56-8 Hydroxyprogesterone caproate

Purelife Supply High Quality Natural Water Soluble Lutein Marigold Flower Extract

Halal Free Sample Cornus Officinalis Fruit Extract 10:1Cornus officinalis extract factory supply Dog

Top Quality Food Grade Probiotics Supply Lactobacillus Bifidobacterium Infantis Powder

Chilli pepper oil in bulk supply, worldwide fast delivery

Instock Export Factory Supply Natural Anti-virus Ban Lan Gen Radix Isatidis Extract Powder

Manufacture Supply CAS 607-80-7 ISO Approved 98% Sesamin Black Sesame Seed Extract

Factory Supply Free Sample mango seed powder

HUAJIN Pharma Factory Supply Transfer Factor Capsules Biochemical medicine

Centre provides over 42 crore vaccine doses to states and UTs

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>